Pd-L1 Ihc 22c3 Pharmdx Demonstrates Precision And Reproducibility In Detecting Pd-L1 Expression In Triple Negative Breast Cancer.

Karina Kulangara,Brittany Watts,Monika Vilardo,Christopher La Placa,Judith Frederick,Siena Tabuena-Frolli,Malinka Jansson,Kristopher Kersch

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览9

暂无评分

摘要

e13104Background: PD-L1 IHC 22C3 pharmDx is an FDA-approved, companion diagnostic assay intended for use in the detection of PD-L1 protein in formalin-fixed paraffin-embedded (FFPE) non-small cell ...

查看译文

关键词

triple negative breast cancer,negative breast cancer,breast cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要